Today is Tuesday, December 8. I’m just finding some time to gather my thoughts from Monday’s abstracts and meetings, and I’m impressed in reading all of the other #IMFASH20 leaders’ blogs. Each perspective is unique and relevant. It’s the patient’s experience and mindset. I really hope you are reading all the leaders’ blogs to get a broad […]
The 62nd annual meeting of the American Society of Hematology (ASH) does not officially start until 12.4.2020. However, the multiple myeloma experts are always ahead of the curve, having the International Myeloma Working Group (IMWG) “breakfast” meeting 12.2.2020. This year, the meeting was again led by Dr. Brian Durie and Dr. Vincent Rajkumar. The International […]
Today is effectively the final day of ASH but it was still full of information, and to be honest, I’m a bit brain-fried. However, the day was broken up with the opportunity to meet with several Pharma companies: Takeda (Velcade, Ninlaro), who discussed their new Patient Advocacy Liaisons (Oncology Nurses) who will offer presentations to […]
“Folks. This COVID thing is real. When a solution (vaccines) is around the corner it isa huge tragedy if we cannot come together for a common goal: Save lives.” —Dr. S. Vincent Rajkumar (Mayo Clinic — Rochester, MN) Stephanie Lee, MD, MPH current president of the ASH, hosted a virtual discussion with Dr. Anthony Fauci, […]
Several sessions have been presented at the 2020 American Society of Hematology’s Annual Meeting, highlighting research data and findings specifically related to myeloma novel targeting agents. There were 2 terms, off-the-shelf and Allogeneic CAR, referred to many times yesterday during immunotherapy sessions. While I felt I understand the context of the discussions, I was immediately […]
The results being presented from clinical trials at ASH give myeloma patients hope. Hope for the future, hope that we will see our children grow up, get married. Hope that we will become grandparents one day. Hope that we will live long enough to enjoy retirement with our spouse or significant other. Hope for a […]
In our Support Group Leader team discussion, the subject of T-Cells came up, naturally, with the many abstracts focusing on Chimeric Antigen Receptor-T Cell (CAR-T) therapy at the 62nd Annual American Society (ASH) meeting. What was appreciated is that there are many types of T-Cells, and people wanting to know more about their function. To […]
At last year’s ASH meetings, I learned a tremendous amount about BiTES (bispecific T-cell engagers). I referenced it as getting my feet wet. This year I can say that I not only got my feet wet but was submerged waist deep in emerging Duo Body Bispecific antibodies (BsAbs). Bispecific antibodies, like CAR-T cell therapy are […]
After finishing two full days of watching abstracts and education sessions about multiple myeloma at the American Society of Hematology Conference (ASH), my head is spinning from the number of new combinations, therapies, and therapy targets. All of this is excellent news for us, but this makes treatment decisions much more complicated. This diagram presented by Dr. […]
Today began with watching ASH abstract presentations from yesterday. This is actually one of the benefits of attending the meeting virtually. Presentations are often scheduled at the same time and at the in-person meeting, you need to make a decision which to attend. But being virtual, I’m able to watch a replay of a session […]
